



Ventripoint Welcomes Evelina London Children's Hospital as Newest VMS+ User

Toronto, Ontario – The Newswire – August 22, 2023 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that Evelina London Children's Hospital (part of Guy's and St Thomas' NHS Foundation Trust) is the newest user to adopt the VMS+ 3.0 system upgrade.

Dr. Saleha Kabir, Lead Physiologist in Paediatrics and Advanced Echocardiography stated: "Having had experience with the older Ventripoint system, the new VMS + system with its increased functionality is a great addition to our echo lab. The more compact console increases accessibility and mobility which allows us to use it in a variety of settings and the simplified workflow makes image acquisition faster, which is fantastic for our small and easily distracted paediatric patients!"

Evelina London Children's Hospital is a specialist NHS hospital in London, England and is the second largest provider of children's services in London caring for children and young people from across south London and southeast England. Evelina London has a range of children's heart clinics including the fetal cardiology clinic and arrhythmia clinic. The children's heart services (cardiology) cares for around 6,000 patients each year with all kinds of children's heart problems including:

- those present from birth, known as congenital heart disease.
- those that develop after birth, known as acquired heart disease.
- rhythm disturbances.

The VMS+ 3.0 system will provide the paediatric cardiology team with a way to obtain accurate volumes of all four chambers of the heart. The VMS+ uses standard 2D echo to obtain the necessary metrics with the accuracy of a cardiac MRI. The VMS+ will support Evelina London's patient load and have a positive impact in patient care.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson CFA
JRobinson@oakhillfinancial.ca
(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.